Vigil Neuroscience is a microglia-focused therapeutics company
Our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of microglia, the brain’s sentinel immune cells. We are harnessing the tools of modern neuroscience to develop and deliver precision-based therapies to improve the lives of patients and their families.
OUR APPROACH
Leveraging recent discoveries implicating the pivotal role of microglial dysfunction in neurodegenerative diseases, we are applying a precision medicine approach to develop novel microglia-targeted drug candidates for genetically defined patient subpopulations. Our goal ultimately is to develop therapies for larger patient populations, leveraging learnings from our initial precision-based programs.
OUR PROGRAMS
Our most advanced therapeutic programs are aimed at developing highly selective activators of TREM2, a membrane spanning receptor expressed specifically on microglia, resident immune sentinel cells in the brain. TREM2 plays a critical role in maintaining brain homeostasis, as highlighted by inherited neurodegenerative diseases associated with TREM2 dysfunction.
PATIENTS
Patients are central to our primary objective of developing drugs for rare and common neurodegenerative diseases. Our approach is to collaborate with patients, caregivers, and patient advocacy groups to best serve the patient community.
